Regeneron is a fully integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for serious diseases across therapeutic areas including ophthalmology, immunology, oncology, cardiovascular disease, and rare genetic disorders. The company generates revenue through sales of marketed products such as EYLEA (retinal diseases), Dupixent (allergic and inflammatory diseases), Libtayo (cancer), and others, primarily to wholesalers, specialty distributors, pharmacies, and hospitals, often through strategic partnerships with major pharmaceutical companies like Sanofi and Bayer. Regeneron's competitive advantage rests on proprietary research platforms—including its VelociSuite antibody discovery technologies, CRISPR gene editing, and RNA interference therapeutics—combined with internal manufacturing capabilities and the Regeneron Genetics Center, which uses genomic data from millions of samples to identify novel disease targets and advance drug discovery.